LUND, Sweden, May 14, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) at the Peripheral Nerve Society (PNS)...
Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS )
Also on site :
- Disneyland raises hopes for future Toy Story Midway Mania makeovers
- Thumbprint on cigarette carton leads to arrest in 1977 death of young woman
- PHOTO COLLECTION: Menendez Brothers